Jeff Yass’s Design Therapeutics DSGN Stock Holding History

Jeff Yass’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$579K	Buy	+40,000	New	+$499K	﹤0.01%	9569
2025 Q3	–	Sell	-13,000	Closed	-$43.8K	–	12680
2025 Q2	$43.8K	Buy	+13,000	New	+$48.6K	﹤0.01%	12149
2024 Q1	–	Sell	-91,400	Closed	-$242K	–	12409
2023 Q4	$242K	Sell	91,400 -8,700	-9%	-$19.9K	﹤0.01%	10290
2023 Q3	$236K	Buy	+100,100	New	+$467K	﹤0.01%	9858
2023 Q1	–	Sell	-183,900	Closed	-$1.89M	–	12728
2022 Q4	$1.89M	Buy	183,900 +24,300	+15%	+$329K	﹤0.01%	4812
2022 Q3	$2.67M	Buy	159,600 +100,500	+170%	+$2M	﹤0.01%	4319
2022 Q2	$827K	Buy	+59,100	New	+$798K	﹤0.01%	6998

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jeff Yass's DSGN Position: Q2 2026 in Review

Jeff Yass opened a new position in Design Therapeutics (DSGN) in Q2 2026: 15,650 shares worth $226K. The stake represents ﹤0.01% of the portfolio and ranks #11682 among its holdings. This is a return to the name: Jeff Yass previously reported a position in DSGN as recently as Q4 2025.

Jeff Yass first reported a position in DSGN in Q2 2022 and has held it in 15 quarters since. The position peaked at $1.75M in Q1 2023. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

Jeff Yass held 15,650 shares of Design Therapeutics worth $226K as of Q2 2026.
Design Therapeutics was a new Jeff Yass position in Q2 2026.
Design Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11682 holding.
Jeff Yass first reported a position in Design Therapeutics in Q2 2022 and has held it in 15 quarters since.
Jeff Yass's Design Therapeutics position peaked at $1.75M in Q1 2023.
136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.